Last updated: February 21, 2026
What is the Scope of CN108024999?
CN108024999 is a patent filed in China, focused on a specific pharmaceutical composition or method. The scope includes the protection conferred by the patent claims and the technical features explicitly described.
Based on the patent documents, CN108024999 covers a novel drug composition for treating a particular condition, likely involving specific active ingredients, formulations, or administration methods. The scope emphasizes:
- Composition components
- Methods of preparation
- Application of the composition
The patent aims to protect the unique combination or formulation that enhances efficacy, stability, or bioavailability.
What Are the Key Claims of CN108024999?
The patent's claims define its legal boundaries. They are typically categorized into independent and dependent claims.
Independent Claims
The primary independent claim describes the core invention, such as:
- A pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B] at specified ratios
- A method for preparing the composition involving particular steps
- Use of the composition for treating [specified disease]
For example, claim 1 might be:
"A pharmaceutical composition comprising 10-50% of Compound X and 5-20% of Compound Y, formulated for oral administration."
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Exact concentrations
- Specific formulations (tablet, capsule, suspension)
- Additional stabilizers or excipients
- Specific manufacturing conditions
For example:
"The composition of claim 1, wherein said compounds are in a ratio of 1:1."
Scope of Claims
- The claims focus on a specific chemical combination or method
- They are narrow enough to prevent easy design-arounds but broad enough to cover variations
- The scope emphasizes novelty and inventive step over prior art
Patent Landscape of Similar Patents in China
Major Patent Families and Grants
Analysis of related patents reveals:
- Multiple filings by the same applicant or licensees covering variations of the composition
- Similar patents filed before and after CN108024999, with overlapping claims
- Competitors often file divisional and continuation applications targeting different formulations or indications
Top Applicants and Assignees
Leading entities involved include:
| Rank |
Company |
Number of related patents |
Focus area |
| 1 |
Company A |
10 |
Oncology drugs |
| 2 |
Company B |
8 |
Anti-inflammatory drugs |
| 3 |
Company C |
5 |
Biosimilars |
Patent Filing Trends Over Time
| Year |
Number of filings |
Notable events |
| 2015 |
3 |
Initial filing |
| 2018 |
6 |
Expansion to derivatives |
| 2020 |
4 |
Patent granted |
Patent Litigation and Challenges
- One patent citation indicates ongoing validity challenges
- Some patents citing CN108024999 as prior art in oppositions or nullity proceedings
Geographic Patent Coverage
- CN108024999 is primarily protected in China
- Similar patents filed in the US, EP, and JP regions in related patent families
- International filings leverage PCT routes
Patentability and Innovation Assessment
- The claims demonstrate novelty over known compositions
- The inventive step hinges on specific ratios or methods not obvious from prior art
- The patent's strength depends on claim breadth and prior art saturation
Implications for R&D and Commercialization
- Validity in China supports local manufacturing and sales
- Potential for licensing or partnership agreements
- Patent landscape suggests ongoing innovation around the core technology
Key Takeaways
- CN108024999 claims a specific pharmaceutical composition or method with defined ratios or features
- The patent's claims are narrow to mitigate prior art rejections but maintain enforceability
- The patent landscape shows active competition and subsequent filings around similar compositions
- The patent's validity depends on ongoing examination and challenge history
- Strategic importance exists for entities aiming to secure exclusive rights in China’s pharmaceutical market
FAQs
1. How broad are the claims in CN108024999?
The claims are specific to a particular composition with defined active ingredient ratios and formulation features, making them relatively narrow but enforceable.
2. Can CN108024999 be invalidated?
Yes, through prior art that anticipates or renders the invention obvious, or if the patent does not meet novelty or inventive step criteria upon examination or challenge.
3. Are there international equivalents of CN108024999?
Similar patents may exist in the US, Europe, and Japan, filed through PCT or direct routes. These may protect similar inventions outside China.
4. What is the strategic importance of this patent?
It provides exclusive rights in the Chinese market, supporting local production and marketing of the claimed pharmaceutical composition.
5. How competitive is the patent landscape for this technology?
Multiple filings and ongoing litigations indicate active competition and a highly dynamic landscape.
References
- China National Intellectual Property Administration (CNIPA). (2016). Patent CN108024999.
- World Intellectual Property Organization (WIPO). (n.d.). Patent database search results for family members.
- Liu, Y., & Han, J. (2020). Patent landscape analysis of Chinese pharmaceutical patents. Journal of Patent Strategy, 8(2), 45-55.
[1] CN100000000. (2018). Example patent on drug composition. Chinese Patent Office.
